VERA - Vera Therapeutics boasts of mid-stage data from kidney inflammation candidate atacicept
- A higher dosage strength of Vera Therapeutics ( NASDAQ: VERA ) atacicept, under investigation for the kidney inflammation disorder IgA nephropathy, led to a significant reduction in proteinuria compared to placebo in a phase 2b study.
- Results showed that at 24 weeks, patients on the 150 mg atacicept regimen saw a 41% mean reduction in proteinuria compared to baseline. At 36 weeks, the figure was 47%.
- For the 75 mg dosage, the figures were, respectively, 28% and 29%.
- The results were provided as part of a prespecified per-protocol analysis, which the company said included patients who completed treatment according to protocol.
- Vera ( VERA ) anticipates moving atacicept into phase 3 in the first half of the year . Top-line data is expected in 1H 2025.
- The company expects to submit a Biologics License Application for the candidate in 2H 2025.
- Read why Seeking Alpha contributor BiotechValley Insights recently initiated Vera ( VERA ) as a sell.
For further details see:
Vera Therapeutics boasts of mid-stage data from kidney inflammation candidate atacicept